Julina post-marketing surveillance for postmenopausal osteoporosis in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Julina in clinical practice. A total 100 patients will be recruited and followed 3 years since starting Julina administration.
- Patients who received Julina for postmenopausal osteoporosis
- Patients who are contraindicated based on the product label
Many Locations, Japan
E-mail: [email protected]
Phone: Not Available
Drug use investigation of Julina Tablets 0.5 mg (postmenopausal osteoporosis)